Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696478 | 1.00 | CNR1 (0.52) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL27794445 | 0.83 | L3MBTL1 (0.58) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL1444565 | 0.83 | L3MBTL1 (0.58) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL17470177 | 0.80 | SERPINH1 (0.54) | CNR1KMT2AGAABLML3MBTL1 | |
| SCHEMBL1984774 | 0.80 | SERPINH1 (0.54) | CNR1KMT2AGAABLML3MBTL1 | |
| SCHEMBL267537 | 0.79 | MAPK1 (0.49) | CNR1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL27746042 | 0.79 | CNR1 (0.47) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL28773402 | 0.79 | CNR1 (0.47) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL18590445 | 0.78 | ALDH1A1 (0.53) | CNR1MEN1KMT2AGAABLM | |
| SCHEMBL13986540 | 0.78 | CNR1 (0.48) | CNR1MEN1KMT2AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | SOD1, AOC3, CBR1 | CNR1 739/4885MEN1 3293/4885KMT2A 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.